FDA approves nasal spray for treatment-resistant depression

The spray targets glutamate, the most common excitatory neurotransmitter in the brain

The FDA has approved a nasal spray-based monotherapy for adults living with major depressive disorder (MDD) who have had an inadequate response to at least two oral antidepressants.

The spray, called Spravato CIII (esketamine), works by targeting glutamate, the most common excitatory neurotransmitter in the brain.

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants or cannot tolerate them. For too long, healthcare providers have had few options to offer patients much-needed symptom improvement," said Johnson & Johnson global therapeutic area head, neuroscience, Dr Bill Martin.

"Spravato is now available as a standalone treatment, meaning patients may experience improvements in depressive symptoms as early as 24 hours and at 28 days – without the need for daily oral antidepressants." 

Spravato was tested in a randomised, double-blind, multicentre placebo-controlled study. The spray alone showed quick and superior improvement in Montgovery-Asberg Depression Rating Scale (MADRS) total score compared to the placebo.

All 10 of the MADRS items showed numerical improvements at day 28, and at week four, just over 22% of Spravato patients achieved remission, compared to the 7.6% of placebo patients.

Safety was also tested in the study, which found that Spravato is suitable both as a standalone treatment and when used alongside an oral antidepressant.

MDD is one of the most common psychiatric disorders, with over one third of adult patients unresponsive to oral antidepressants alone.

 

Share This Article
Leave a Comment

Subscribe to our Newsletter

© 2026 Setform Limited.